inTEST (INTT) Q2 EPS Beats Estimates

Core Insights - inTEST reported Q2 2025 results with adjusted earnings per share (Non-GAAP) of $0.03, exceeding the $(0.03) consensus, while revenue reached $28.1 million, slightly above the $28.0 million estimate, despite a 17.2% decline year-over-year [1][2] Financial Performance - Q2 2025 adjusted EBITDA was $1.3 million, marking a return to positive after a loss in the previous quarter [5] - Gross margin improved to 42.6%, up 2.0 percentage points from the previous year, driven by better product mix and cost containment [5][2] - Total orders increased by 6.0% year-over-year and 9.5% sequentially to $27.76 million, with significant growth in automotive/electric vehicle and life sciences sectors [6] Market and Product Focus - inTEST specializes in automated testing and processing technology for various sectors, including semiconductor, automotive, life sciences, and defense/aerospace [3] - The company is focusing on innovation and market diversification, with new products like the SCAiLX Edge AI platform and acquisitions such as Alfamation to drive growth [4] Segment Performance - Semiconductor revenue increased by 0.7% year-over-year to $10.2 million, but orders in this segment fell by 33.9% year-over-year, indicating cautious capital spending [7] - Automotive/EV revenue dropped by 50.0% year-over-year to $6.0 million, affected by customer order timing [7] - Life sciences orders surged by 179.3% year-over-year, reflecting strong performance in that segment [6] Operational Developments - The company is undergoing restructuring to enhance efficiency, with operating expenses projected between $12.6 million and $13.1 million for Q3 2025 [10] - Cash and undrawn term loan capacity stood at $19.2 million at the end of Q2 2025, despite a cash outflow of $2.8 million during the period [10] Future Outlook - Management projects Q3 2025 revenue in the range of $28 million to $30 million, indicating stable or slightly improved sales [12] - Key watch points include the recovery pace of semiconductor orders, execution of cost reductions, and progress in automotive/EV and life sciences segments [13]